Ipamorelin: What the Research Actually Says

Research use only. Not for human consumption.

What it is

Ipamorelin is a synthetic pentapeptide — five amino acids in the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — developed by Novo Nordisk in the late 1990s (research designation NNC 26-0161). It belongs to the growth hormone secretagogue (GHS) class and works as a ghrelin mimetic: it binds the GHS-R1a receptor in the pituitary and triggers a pulse of the body’s own growth hormone. It’s the compound most often paired with CJC-1295 No DAC in the popular GH-axis stack.

Its whole reputation rests on one word: selectivity. The non-natural amino acids in its structure — aminoisobutyric acid at the N-terminus, D-amino acids through the chain — were deliberate design choices to resist enzymatic breakdown and sharpen receptor binding. The result is a peptide that releases GH without meaningfully raising cortisol, ACTH, prolactin, or the other hormones that make older GHRPs (like GHRP-2 and GHRP-6) messier. Hold onto that selectivity claim — it’s real, and it’s also where the story gets interesting.

Animal data

This is Ipamorelin’s strongest ground. The foundational work — Raun and colleagues (1998, European Journal of Endocrinology) — described it as “the first selective growth hormone secretagogue,” documenting GH release in swine at potency comparable to GHRP-6 but without the ACTH, cortisol, FSH, LH, prolactin, or TSH elevations seen with older compounds, even at doses more than 200-fold above the GH-releasing threshold. The selectivity wasn’t a marketing invention; it came straight out of the original characterization.

Follow-on rodent work reinforced the profile: stimulation of longitudinal bone growth (Johansen et al.), counteraction of glucocorticoid-induced reductions in bone formation, and accelerated gastric emptying in models of impaired gut motility via GHS-R1a-mediated cholinergic pathways. In animals, Ipamorelin does exactly what it claims — a clean, selective GH pulse.

Human data

Here’s where the honest angle sharpens — and it’s a different problem than the one CJC-1295 or TB-500 had. With those, the catch was a molecular bait-and-switch: the human data everyone cites studied a different compound. Ipamorelin has no such swap. The molecule studied in humans genuinely is Ipamorelin. The gap is elsewhere: the benefits people actually buy it for have never been tested in humans at all.

There is no human trial of Ipamorelin for fat loss, lean mass, recovery, or “anti-aging.” That entire use case rests on mechanism and extrapolation. The single completed human efficacy trial studied something else entirely: Beck and colleagues (2014, International Journal of Colorectal Disease; NCT00672074) ran a Phase 2, multicenter, double-blind, placebo-controlled study of IV Ipamorelin for postoperative ileus — the temporary gut paralysis that follows abdominal surgery. Of 117 enrolled, 114 bowel-resection patients received 0.03 mg/kg or placebo twice daily.

The result: it missed its primary endpoint. Median time to tolerate a solid meal was 25.3 hours on Ipamorelin versus 32.6 hours on placebo — a trend in the right direction, but not statistically significant (p=0.15). The compound was well-tolerated, which is where most of the limited human safety data comes from. But efficacy wasn’t demonstrated, and the developer discontinued the program afterward. There are no Phase 3 trials and no FDA approval for any indication. So the human file reads: one failed efficacy trial for an indication nobody buys it for, some early pharmacokinetic work — and nothing on the things it’s actually marketed for.

Promising vs. overhyped

Genuinely promising: The selectivity is real, replicated, and mechanistically clean — that’s more than most peptides in this series can claim. Ipamorelin unambiguously does release GH in a selective, pulsatile way that mimics natural secretion. And unlike its stack-mate CJC-1295 No DAC, or TB-500, there’s no bait-and-switch here: the compound studied is the compound sold.

Overhyped: A confirmed mechanism is not a confirmed outcome. “It selectively releases GH in animals” is a very different statement from “it improves body composition, recovery, or aging markers in humans” — and that second statement has never been tested. The popular CJC-1295 + Ipamorelin combination is a mechanistically sensible pairing with zero human efficacy trials behind it. And the one human efficacy trial that did run, missed. The marketed benefits live entirely in the space between a real mechanism and the human outcome studies that were never done.

Regulatory reality

Ipamorelin has never been FDA-approved for any indication, and its 2026 status is genuinely unsettled — a step behind some of its peers. It was placed in the FDA’s 503A Category 2 (barred from pharmacy compounding) in late 2023, then removed in September 2024 after the nominators withdrew — but the Pharmacy Compounding Advisory Committee subsequently voted against adding it to the permitted 503A list. Following the February 2026 HHS announcement signaling several peptides might return to Category 1, and the FDA’s April 2026 list updates, Ipamorelin sits in a classification gap: off the restricted list, not cleared, and notably not among the seven peptides slated for the July 2026 PCAC review. Removal from Category 2 is a step, not a clearance — and none of it confers FDA approval, validated dosing, or established benefit.

To be precise: that framework governs clinical compounding for human use, a separate track from research-grade material supplied strictly for laboratory work. In sport, there’s no ambiguity — Ipamorelin is on the WADA Prohibited List at all times, in and out of competition, as a GH secretagogue (Section S2). It is not a federally scheduled controlled substance in the U.S. Products in the research market are sold labeled for laboratory research only — not for human consumption.

Hype vs. Evidence rating: 3/5

Ipamorelin earns a 3/5 — the same tier as CJC-1295, a step above BPC-157 and TB-500, but for its own distinct reasons. What lifts it: the selectivity is genuinely established, and alone among the peptides in this series so far, the compound studied is the compound sold — no molecular bait-and-switch inflating its case. What holds it there: the entire marketed use case has zero human data, the single human efficacy trial it did complete missed its endpoint, and development was abandoned. A real, selective, well-characterized mechanism — riding on preclinical strength, with no human outcome evidence for anything a buyer is actually hoping for.

Research use only. Not for human consumption. This content is educational and does not constitute medical advice or dosing guidance.